linjc16/ctgov huggingface dataset:
Palliative Care Unit Transfert Announcements

Study Overview
=================
Brief Summary
-----------------
The course of care of a patient with a cancer whose evolution is pejorative, is marked by difficult announcements, called bad news. In the palliative phase, prognostic announcements are at the forefront. Of these, the announcement of a transfer to the Palliative Care Unit has not been the subject of any specific studies to the best of our knowledge. It therefore seemed interesting to us to explore the stakes of this particular announcement, a source of upheaval for the doctor and the patient, by gathering the point of view of each one. The objective of our study is to analyze the methods of announcing a transfer to the Palliative Care Unit and the perception of this announcement by the doctor and his patient with an incurable cancer.

Official Title
-----------------
Palliative Care Transfer Announcements: Qualitative Analysis of the Perspective of Physicians and Their Patients With Cancer

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP and informed of this transfer by the originating doctor . HUS senior hospital doctors, supporting patients with solid cancers or malignant hemopathies. Exclusion Criteria: Patients whose clinical state does not allow for maintenance (tiredness, confusion) or difficult communication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of semi-structured interviews exploring how the physician analyzes and feels the announcement of the transfer to the Palliative Care Unit and how the patient receives and disseminates this information |  | 72 hours after the transfer of the patient the to the Palliative Care Unit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer, incurable pathologies, palliative care
Allo BMT in Advanced Leukemia or High Grade Lymphoma

Study Overview
=================
Brief Summary
-----------------
To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Detailed Description
-----------------
To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Official Title
-----------------
Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma

Conditions
-----------------
Lymphoma, Non-Hodgkin, Leukemia, Blood and Marrow Transplant (BMT), Lymphomas: Non-Hodgkin

Intervention / Treatment
-----------------
* Procedure: ablative allogeneic hematopoietic cell transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:HLA identical donor adequate organ function other life threatening disease

Ages Eligible for Study
-----------------
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: ablative allogeneic hematopoietic cell transplantation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | october 2009 | 
| disease free survival |  | October 2009 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| early and late toxicities of the treatment regimen |  | October 2009 |
Evaluation of Biomarkers of COPD Exacerbation

Study Overview
=================
Brief Summary
-----------------
Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in patients with stable COPD and AE-COPD.

Detailed Description
-----------------
Patient enrolment and data aquisition is to be carried out on a prospective basis. It is planned to enrol 40 patients with stable COPD and 40 patients with AE-COPD. All patients will undergo blood sampling inlcuding SAA and Lipoxin A4.

Official Title
-----------------
Evaluation of Biomarkers of COPD Exacerbation

Conditions
-----------------
SAA Level and SAA/Lipoxin A4 Ratio

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with COPD GOLD 3-4 confirmed by anamnesis and pulmonary function test Patient has provided written informed consent Exclusion Criteria: other reasons for worsening of symptoms (cough, dyspnea): e.g. pneumothorax, pneumonia, pulmonary embolism, myocardial infarction. malignant disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with stable COPD<br>Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen | |
| Patient with COPD exacerbation<br>Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SAA | SAA level in stable COPD and COPD exacerbation | time of exacerbation/hospitalisation, an average of 3 days | 
| SAA/lipoxin A4 ratio | SAA/lipoxin A4 ratio in stable COPD and COPD exacerbation | time of exacerbation/hospitalisation, an average of 3 days |
Calcium Phosphate and Incretins

Study Overview
=================
Brief Summary
-----------------
The study was conducted to investigate the effect of a calcium phosphate supplementation on the secretion of incretins.

Official Title
-----------------
Influence of a Calcium Phosphate Supplementation on the Secretion of Incretins in Humans.

Conditions
-----------------
Healthy Men

Intervention / Treatment
-----------------
* Dietary Supplement: calcium phosphate
* Other: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy men Exclusion Criteria: intake of dietary supplements and chronic diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: calcium phosphate<br> | Dietary Supplement: calcium phosphate<br>* the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day<br>|
| Placebo Comparator: placebo<br> | Other: placebo<br>* the subjects consumed a bread without pentacalcium phosphate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| secretion of incretins |  | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentration of minerals in plasma |  | 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcium phosphate, incretins, human study
Characterization of Pulmonary Langerhans Cell Histiocytosis

Study Overview
=================
Brief Summary
-----------------
Very recent studies indicate that a high percentage of HCL, about 50%, have mutations in the B-RAF oncogene. The development of ultrasensitive methodologies capable of identifying these mutations in bronchoalveolar lavage will represent a significant advance in the diagnosis and treatment of these patients. An undetermined percentage of HCL does not present mutations in B-RAF. Consequently, the deep genetic analysis, through the use of techniques of massive sequencing, can favor the identification of new alterations that contribute to the development of the disease. We hypothesized that patients with HCL may present a different inflammatory state to healthy subjects or smokers, allowing us to identify new biomarkers.

Detailed Description
-----------------
The main objective of this study is to expand the genetic and pathophysiological knowledge of this disease. For this, the following points will be developed: Identification of mutations in the B-RAF oncogene in Spanish patients with pulmonary LCHF. Development of ultrasensitive genetic analysis methods capable of identifying mutations in B-RAF in bronchoalveolar lavage (BAL) samples. To determine if patients with mutations in the B-RAF oncogene present distinct clinical, radiological and / or functional characteristics compared to those with absence of the mutation. Characterization of the inflammatory profile of patients with HPCL.

Official Title
-----------------
Functional and Genetical Characterization of Pulmonary Langerhans Cell Histiocytosis: Diagnostic and Therapeutical Implications.

Conditions
-----------------
Langerhans Cell Histiocytoses

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Men and women with no age limitation Established histiological diagnosis of histiocytosis of langerhans cells. HCLP-compatible clinical-radiological picture. Signed informed consent Exclusion criteria Non-acceptance of informed consent. Absence in clinical history of clinical, radiological and functional variables essential for the diagnosis of HLCP. Psychiatric disorder or limitation for study compression (including language, socio-cultural problem, etc.). Radiological findings suggestive of another chronic lung disease. Active respiratory infection.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with mutations in the B-RAF oncogene in Langerhans histiocytosis |  | Baseline |
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical study is to assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer

Official Title
-----------------
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: BMS-641988 (AR#2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL progressive to current therapy who satisfy the inclusion and exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A1<br>Active | Drug: BMS-641988 (AR#2)<br>* Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety and tolerability of BMS-641988 once daily orally in Japanese patients with castration resistant prostate cancer |  | throughout the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the pharmacokinetics of BMS-641988 and the metabolites BMS-501949 and BMS-570511 |  | at cycle 1 day 1, day 15 and day 29 | 
| To identify the dose(s) of BMS-641988 for Phase II |  | at the end of study | 
| To assess any preliminary evidence of anti-tumor activity by PSA decline, tumor shrinkage, radionuclide bone scans |  | throughout the study | 
| To assess the effects of BMS-641988 on pharmacodynamic markers (LH, total and free testosterone, 5(alpha)-DHT, estradiol, prolactin, FSH, and SHBG) |  | throughout the study |
Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to evaluate the factors affecting the ability and willingness of dentists to work during the COVID-19 pandemic and the effect of this situation on occupational burnout. A 51-question survey, including demographic and pandemic questions and the Maslach Burnout Inventory (MBI), was used as a data collection method and administered to dentists in Turkey via the internet in two stages. A link to the survey (onlineanketler.com) was sent to the participants by e-mail or social media (WhatsApp©). A total of 706 participants were included in the study. The second stage of the survey only applied to dentists who are assigned within the scope of COVID-19 measures in Turkey.

Official Title
-----------------
Attitudes and Predictive Factors of Psychological Distress and Occupational Burnout Among Dentists During COVID-19 Pandemic in Turkey

Conditions
-----------------
Burnout, COVID-19, Dentistry, Filiation, Pandemic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All dentist working during the COVID-19 outbreak Accepted electronically to participate in our study Completed and submitted our electronic questionnaires successfully Exclusion Criteria: Non-dentists Did not accept electronically to participate in our study Did not complete not submitted our electronic questionnaires successfully
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 706 of participants' burnout (MBI) and stress levels during the Covid 19 pandemic process assessed with survey. |  | 3 Months |
Sphenopalatine Ganglion Block for Post-Dural Puncture Headache

Study Overview
=================
Brief Summary
-----------------
The investigators are attempting to determine a less invasive method of treatment for postdural puncture headaches that can occur after regional anesthesia. The investigators will be evaluating the relief of headache with those subjects receiving treatment with a sphenopalatine ganglion block with bupivacaine versus placebo, evaluating the incidence of epidural blood patch, pain score of headache at 1 hour, then 24, 48, and 72 hours lower with post study treatment versus placebo, and potential side effects of those patients receiving study therapy as well as epidural blood patch.

Official Title
-----------------
Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache: A Prospective Randomized Double Blind Placebo Controlled Study

Conditions
-----------------
Postdural Puncture Headache, Sphenopalatine Ganglion Block

Intervention / Treatment
-----------------
* Drug: bupivacaine
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists assigned class I-III age >/= 18 years experiencing a postdural puncture headache within 7 days of neuraxial analgesia rated >3/10 pain score Exclusion Criteria: allergy to study medications <18 years of age pain score on presentation </=3/10 for headache

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: placebo<br>sphenopalatine ganglion block performed with normal saline as the placebo | Drug: placebo<br> <br> |
| Active Comparator: bupivacaine<br>sphenopalatine ganglion block performed with bupivacaine | Drug: bupivacaine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| verbal pain score | a reduction in headache verbal pain score by 3 | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| epidural blood patch | evaluating the decrease in the necessity of an epidural blood patch to treat the postdural puncture headache | 7 days | 
| patient satisfaction | patient satisfaction with headache pain relief at 1 hour post treatment | 1 hour | 
| pain score | verbal pain score 30 minutes post study treatment | 30 minutes | 
| pain score | verbal pain score 7 days post study treatment | 7 days |
Association Between Different Blood Groups and Sepsis in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
To investigate whether there is a relationship between sepsis and blood groups in preterm infants.This retrospective cohort study included preterm neonates born at <32 weeks of gestation with a birth weight <1500 g. Neonates were grouped by blood type (O, A, B, AB) and sepsis were compared among these groups.

Detailed Description
-----------------
This retrospective study was conducted on data collected between 1 January 2011 and 31 August 2018 in the neonatal intensive care unit (NICU) of the Health Sciences University Zekai Tahir Burak Women's Health Education and Research Hospital. Neonates born at GA <32 weeks with birth weight (BW) <1500 g were included in the study. Data pertaining to the neonates were recorded from medical records for each patient, and their ABO blood type was recorded. The neonates were grouped by blood type (O, A, B, AB) and also separated into non-O (A, B, AB) and O groups and non-A (O, B, AB) and A groups for comparison of early and late onset sepsis.

Official Title
-----------------
Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Clinical Professor

Conditions
-----------------
Blood Group Antigen Abnormality, Prematurity, Sepsis

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm neonates born at <32 weeks of gestation with a birth weight <1500 g. Exclusion Criteria: Neonates born with severe congenital defects, birth weight ≥1500 g and gestational age ≥32 weeks were excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A blood group<br>prematurity with sepsis | Diagnostic Test: Diagnosis<br>* biochemistry<br>|
| O blood group<br>prematurity with sepsis | Diagnostic Test: Diagnosis<br>* biochemistry<br>|
| B blood group<br>prematurity with sepsis | Diagnostic Test: Diagnosis<br>* biochemistry<br>|
| AB blood group<br>prematurity with sepsis | Diagnostic Test: Diagnosis<br>* biochemistry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Association Between Different Blood Groups and Sepsis in Preterm Infants | The neonates were grouped by blood type (O, A, B, AB) and also separated into non-O (A, B, AB) and O groups and non-A (O, B, AB) and A groups for comparison of demographic characteristics, clinical features, and sepsis. | Through study completion, an average of 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood group, sepsis, preterms